3 completed, 2 recruiting. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 2 |
| Phase 1 | 4 | Completed 3, Recruiting 1 |
Follow Cantargia AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunoprevention for High-risk Lung Lesions Nadunolimab - High-risk Lung Nodules | Phase 2 | Recruiting | Robert Samstein | 59 | 2026-05-21 | 2026-06-08 |
| Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC Nadunolimab, Toripalimab - Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Dan Feng | 24 | 2025-12-01 | 2026-02-19 |
| Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. Carboplatin, Gemcitabine, Nadunolimab - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | Cantargia AB | 117 | 2022-01-11 | 2026-05-27 |
| A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors CAN04 (nadunolimab), mFOLFOX, DTX - Advanced Solid Tumors, Colorectal Cancer | Phase 1 / Phase 2 | Completed | Cantargia AB | 40 | 2021-09-22 | 2023-07-03 |
| A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors CAN04, Cisplatin, Gemcitabine - Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Completed | Cantargia AB | 167 | 2017-09-19 | 2024-08-22 |
Colorectal Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Triple Negative Breast Neoplasms (2) · Biliary Tract Neoplasms (1) · Neoplasms (1)
Gemcitabine (3) · Carboplatin (2) · Cisplatin (2) · 130-nm albumin-bound paclitaxel (1) · Docetaxel (1) · Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1) · Pemetrexed (1) · toripalimab (1)
Spain (3) · United States (2) · Austria (1) · Belgium (1) · Denmark (1) · Estonia (1) · France (1) · Germany (1) · Latvia (1) · Lithuania (1) · Netherlands (1) · Norway (1) · Sweden (1)
Ahmad Awada, Professor (1) · Dan Feng, MD, PhD (1) · Ignacio Garcia-Ribas, MD, PhD (1) · Robert M Samstein, MD, PhD (1) · Thomas Marron, MD, PhD (1)
2017 (1)